Renaissance Technologies LLC Sells 166,800 Shares of Xeris Biopharma Holdings, Inc. $XERS

Renaissance Technologies LLC lessened its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 26.9% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 452,860 shares of the company’s stock after selling 166,800 shares during the quarter. Renaissance Technologies LLC’s holdings in Xeris Biopharma were worth $2,627,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Granahan Investment Management LLC grew its stake in Xeris Biopharma by 249.4% in the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after acquiring an additional 873,236 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after acquiring an additional 1,358,760 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Xeris Biopharma during the first quarter valued at approximately $1,204,000. Jefferies Financial Group Inc. purchased a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $689,000. Finally, Ishara Investments LP purchased a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $6,280,000. Institutional investors own 42.75% of the company’s stock.

Insider Buying and Selling

In other Xeris Biopharma news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the sale, the director owned 126,500 shares in the company, valued at $770,385. This represents a 11.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the sale, the insider directly owned 1,691,126 shares in the company, valued at $13,579,741.78. This trade represents a 5.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 266,499 shares of company stock valued at $1,996,417 over the last ninety days. Company insiders own 4.35% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on XERS. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $7.93 on Monday. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -72.09 and a beta of 0.66. The company’s 50-day simple moving average is $7.68 and its two-hundred day simple moving average is $6.79.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 158.10% and a negative net margin of 5.12%.The business had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.03 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.